Diabetes Research and Clinical Practice
Volume 62, Issue 3 , Pages 187-195 , December 2003

Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?

  • James K. Malone

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-317-277-6472; fax: +1-317-277-5458
    • ,
  • Scott D. Beattie

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • Barbara N. Campaigne

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • Patricia A. Johnson

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • Andrew S. Howard

      Affiliations

    • Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    • ,
  • Zvonko Milicevic

      Affiliations

    • Eli Lilly and Company, Regional Operations GES, M.B.H., Vienna, Austria

Received 2 May 2002 ,Revised 19 June 2003 ,Accepted 4 August 2003.

References 

  1. R.A. DeFronzo, A.M. Goodman, and the Multicenter Metformin Study Group, Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus, N. Engl. J. Med. 333 (1995) 541–549.
  2. European Diabetes Policy Group, A desktop guide to type 2 diabetes mellitus, Ann. Intern. Med. 16 (1999) 716–730.
  3. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N. Engl. J. Med. 329 (1993) 977–986.
  4. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus. A randomized prospective 6-year study. Diab. Res. Clin. Pract. 1995;28:103–117
  5. UK Prospective Diabetes Study Group, UK Prospective Diabetes Study 33: Intensive blood–glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes, Lancet 352 (1998) 837–853.
  6. American Diabetes Association, Postprandial blood glucose, Diabetes Care 24 (2001) 775–778.
  7. Anderson JH, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes. 1997;46:265–270
  8. Anderson Jr JH, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch. Intern. Med. 1997;157:1249–1255
  9. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care. 1999;22:1258–1261
  10. Roach P, Trautmann M, Arora V, Sun B, Anderson JH. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, Insulin Lispro Mix25 and Insulin Lispro Mix50. Clin. Ther. 1999;21:523–534
  11. J.C. Pickup, G. Williams (Eds.), Classification and diagnosis of diabetes mellitus and impaired glucose tolerance, in: Textbook of Diabetes, vol. 1, Blackwell Scientific Publications, Oxford, UK, 1991, p. 39.
  12. S.A. Ross, B. Zinman, R.V. Campos, T. Strack, Canadian Lispro Study Group, A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents, Clin. Invest. Med. 24 (2001) 292–298.
  13. Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care. 2000;23:1236–1241
  14. Kowalska I, Prokop J, Bachorzewska-Gajewska H, et al.  Disturbances of glucose metabolism in men referred for coronary arteriography: postload glycemia as a predictor of coronary atheriosclerosis. Diabetes Care. 2001;24:897–901
  15. Temelkova-Kurktschiev T, Henkel E, Schaper F, et al.  Prevalence and atherosclerosis risk in different types of non-diabetic hyperglycemia. Is mild hyperglycemia an underestimated evil?. Exp. Clin. Endocrinol. Diabetes. 2000;108:93–99

PII: S0168-8227(03)00181-5

doi: 10.1016/j.diabres.2003.08.003

Diabetes Research and Clinical Practice
Volume 62, Issue 3 , Pages 187-195 , December 2003

Article Tools

* Image Usage & Resolution